Protocol Ledger

NCT05035030 · Phase III · ACTIVE NOT RECRUITING

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

Interventional Phase III clinical trial protocol NCT05035030 sponsored by Albireo, an Ipsen Company in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-03 Enrollment: 62 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05035030
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)62 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05035030
Protocol FieldVerified Registry Value
NCT IdentifierNCT05035030
Consolidated Lead SponsorAlbireo, an Ipsen Company
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment62 participants (ACTUAL)
Registered Start Date2021-09-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI